<DOC>
	<DOCNO>NCT02005159</DOCNO>
	<brief_summary>Provide scientific validate data help International Authorities set susceptible antibiotic cut-off point bacteremia Enterobacteriaceae</brief_summary>
	<brief_title>Study Impact Minimum Inhibitory Concentration Susceptible Cut-off Points ( CLSI , EUCAST , Pharmacokinetics/Pharmacodynamics ) Prognosis Bacteremia Enterobacteriaceae</brief_title>
	<detailed_description />
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>&gt; 17 year old Clinically significant bacteremia Have receive treatment fulfil criterion : 1 . Treated active antibiotic enterobacteria ( association vancomycin , linezolid , daptomycin , metronidazole clindamycin ) : cefotaxime , ceftriaxone , ceftazidime , cefepime , amoxicillin/clavulanic , piperacillin/tazobactam , ertapenem , imipenem , meropenem , ciprofloxacin levofloxacin 2 . First antibiotic dose administer first 12 hour time sample 3 . The antibiotic dosage least advised amount summary product characteristic patient renal function 4 . The antibiotic administer least 48 hour .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Enterobacteria</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Minimum inhibitory concentration</keyword>
	<keyword>Susceptible</keyword>
	<keyword>Prognosis</keyword>
</DOC>